We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+25.43%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$16.7B
AUM Growth
+$1.38B
Cap. Flow
-$374M
Cap. Flow %
-2.25%
Top 10 Hldgs %
86.98%
Holding
128
New
13
Increased
17
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$37.7M
2
PRME icon
Prime Medicine
PRME
+$18.6M
3
DNLI icon
Denali Therapeutics
DNLI
+$14.9M
4
REPL icon
Replimune Group
REPL
+$14.2M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$13M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$254M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$92.6M
3
TVTX icon
Travere Therapeutics
TVTX
+$44M
4
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$37.6M
5
RLMD icon
Relmada Therapeutics
RLMD
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
2 Miscellaneous 0.16%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
76
Revolution Medicines
RVMD
$44B
$5.29M 0.03%
222,222
– –
EWTX icon
77
Edgewise Therapeutics
EWTX
$4.82B
$4.47M 0.03%
500,000
– –
PRAX icon
78
Praxis Precision Medicines
PRAX
$9.23B
$4.36M 0.03%
+122,021
New +$3.81M
TCRX icon
79
TScan Therapeutics
TCRX
$21.7M
$4.32M 0.03%
2,784,792
– –
ARAV
80
DELISTED
Aravive, Inc. Common Stock
ARAV
$4.3M 0.03%
+3,261,224
New +$4.16M
CYT
81
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$4.11M 0.02%
2,492,118
-151,522
-6% -$243K
NTRA icon
82
Natera
NTRA
$47.4B
$4.02M 0.02%
100,000
– –
TLIS
83
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$3.4M 0.02%
508,322
– –
TIL icon
84
Instil Bio
TIL
$50.1M
$3.32M 0.02%
263,689
+69,004
+35% +$3.41M
XNCR icon
85
Xencor
XNCR
$1.81B
$3.21M 0.02%
+123,127
New +$3.44M
ITOS
86
DELISTED
iTeos Therapeutics
ITOS
$2.94M 0.02%
150,346
– –
KALA icon
87
KALA BIO
KALA
$11.1M
$2.93M 0.02%
+1,536
New +$608K
BCEL
88
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.83M 0.02%
3,532,760
– –
HOOK
89
DELISTED
HOOKIPA Pharma
HOOK
$2.82M 0.02%
347,554
+107,506
+45% +$1.16M
PMVP icon
90
PMV Pharmaceuticals
PMVP
$78M
$2.8M 0.02%
322,024
– –
ATRA icon
91
Atara Biotherapeutics
ATRA
$94.2M
$2.44M 0.01%
29,767
– –
NKTX icon
92
Nkarta
NKTX
$208M
$2.4M 0.01%
400,000
– –
PCVX icon
93
Vaxcyte
PCVX
$8.86B
$2.34M 0.01%
+48,885
New +$1.92M
ACHL
94
DELISTED
Achilles Therapeutics
ACHL
$2.33M 0.01%
2,591,366
– –
FATE icon
95
Fate Therapeutics
FATE
$277M
$2.18M 0.01%
215,695
– –
ALGS icon
96
Aligos Therapeutics
ALGS
$32.6M
$1.98M 0.01%
83,056
– –
NGNE icon
97
Neurogene
NGNE
$710M
$1.95M 0.01%
191,087
– –
KRON
98
DELISTED
Kronos Bio
KRON
$1.94M 0.01%
1,198,151
-341,465
-22% -$786K
SYRE icon
99
Spyre Therapeutics
SYRE
$7.99B
$1.53M 0.01%
136,404
– –
TCRR
100
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$752K ﹤0.01%
753,064
– –
2 3
4
5 6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Baker Bros. Advisors held 128 positions worth $16.7B, up 9.1% from $15.3B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors's Q4 2022 filing shows 13 new, 17 increased, 8 reduced and 15 closed positions. Its largest new stake was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M. The largest sale was Global Blood Therapeutics, Inc., an estimated $254M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Financials.

  • Baker Bros. Advisors's largest Q4 2022 buy was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M.
  • Baker Bros. Advisors added most to Denali Therapeutics in Q4 2022, an estimated $14.9M increase.
  • Baker Bros. Advisors's biggest Q4 2022 reduction was Travere Therapeutics, cutting an estimated $44M.
  • Baker Bros. Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $254M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $16.7B portfolio in Q4 2022.
  • Baker Bros. Advisors opened 13 new positions and closed 15 in Q4 2022.
  • Baker Bros. Advisors's portfolio value rose 9.1% quarter-over-quarter to $16.7B.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.